Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — N-acetylcysteine for COVID-19: real-time meta analysis of 24 studies

@CovidAnalysis, May 2024, Version 2V2
Post
Share
PDF
Studies
Feedback
https://c19early.org/nacmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1​ Improvement, RR [CI] Treatment Control Altay (DB RCT) 83% 0.17 [0.13-0.24] no recov. 229 (n) 75 (n) CT​1​ Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 de Alencar (DB RCT) -16% 1.16 [0.59-2.01] ventilation 16/67 14/68 de Alencar (DB RCT) 9% 0.91 [0.59-1.28] ICU 29/67 32/68 de Alencar (DB RCT) -12% 1.12 [0.77-1.65] ICU 67 (n) 68 (n) de Alencar (DB RCT) -10% 1.10 [0.37-3.23] hosp. time 67 (n) 68 (n) Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Gaynitdinova (RCT) 51% 0.49 [0.32-0.75] Ct imp. 24 (n) 22 (n) Pellegrini 52% 0.48 [0.33-0.70] death 138 (n) 726 (n) Pourhoseingholi 11% 0.89 [0.68-1.18] death 65/309 274/2,159 Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Taher (DB RCT) 14% 0.86 [0.53-1.40] ventilation 18/47 20/45 Taher (DB RCT) 20% 0.80 [0.44-1.47] ICU 47 (n) 45 (n) Taher (DB RCT) 33% 0.67 [0.31-1.45] hosp. time 47 (n) 45 (n) Taher (DB RCT) 15% 0.85 [0.60-1.22] no recov. 25/47 28/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 Avdeev 77% 0.23 [0.03-1.90] ventilation 1/24 4/22 Avdeev 77% 0.23 [0.03-1.90] ICU 1/24 4/22 Avdeev 15% 0.85 [0.75-0.96] hosp. time 24 (n) 22 (n) STORM Faverio (PSW) -19% 1.19 [0.85-1.66] death 91/572 44/329 STORM Faverio (PSW) -34% 1.34 [0.97-1.84] ICU 107/572 46/329 STORM Faverio (PSW) 1% 0.99 [0.81-1.20] no disch. 180/572 105/329 Ramadhan -135% 2.35 [0.33-16.9] death 11/75 1/16 Izquierdo 26% 0.74 [0.63-0.88] death 136/2,071 1,935/17,137 Delić (RCT) 10% 0.90 [0.63-1.30] death 21/39 31/52 Intubated patients Fariña-González 39% 0.61 [0.34-1.09] death 10/38 44/102 Intubated patients Mousapour (DB RCT) 2% 0.98 [0.26-3.64] death 4/42 4/41 Mousapour (DB RCT) 27% 0.73 [0.28-1.93] ventilation 6/42 8/41 Mousapour (DB RCT) 6% 0.94 [0.67-1.32] no improv. 25/42 26/41 Mousapour (DB RCT) 5% 0.95 [0.74-1.21] no disch. 31/42 32/41 Rahimi (SB RCT) 33% 0.67 [0.40-1.11] death 10/20 15/20 ICU patients Rahimi (SB RCT) 8% 0.92 [0.68-1.26] hosp. time 20 (n) 20 (n) ICU patients Çavuş (ICU) -13% 1.13 [0.85-1.50] death 52/97 44/93 ICU patients Çavuş (ICU) -20% 1.20 [0.91-1.58] ventilation 55/97 44/93 ICU patients Çavuş (ICU) 12% 0.88 [0.55-1.39] ICU 97 (n) 93 (n) ICU patients Çavuş (ICU) 13% 0.87 [0.74-1.02] hosp. time 97 (n) 93 (n) ICU patients Panahi (RCT) 92% 0.08 [0.03-0.22] death 4/125 49/125 Inhaled Panahi (RCT) 36% 0.64 [0.29-1.43] ICU 9/125 14/125 Inhaled Panahi (RCT) 1% 0.99 [0.94-1.05] hosp. time 125 (n) 125 (n) Inhaled Gamarra-Mo.. (RCT) 16% 0.84 [0.55-1.29] death 25/72 28/68 ICU patients Afaghi 29% 0.71 [0.33-1.52] death 10/217 16/245 Afaghi 41% 0.59 [0.30-1.16] ventilation 12/217 23/245 Afaghi 20% 0.80 [0.51-1.24] ICU 29/217 41/245 Afaghi 14% 0.86 [0.79-0.95] hosp. time 217 (n) 245 (n) Sherkawy (RCT) 0% 1.00 [0.07-15.3] death 1/30 1/30 Sherkawy (RCT) 15% 0.85 [0.57-1.27] oxygen 17/30 20/30 Sherkawy (RCT) 33% 0.67 [0.50-0.88] oxygen time 30 (n) 30 (n) Sherkawy (RCT) 12% 0.88 [0.62-1.23] hosp. time 30 (n) 30 (n) Galindo-Andúgar 43% 0.57 [0.31-0.99] death 199 (n) 179 (n) Atefi (SB RCT) 67% 0.33 [0.04-3.03] death 1/30 3/30 Huh 26% 0.74 [0.68-0.80] cases population-based cohort N-acetylcysteine COVID-19 outcomes c19early.org May 2024 ​1​ CT: study uses combined treatment Favors N-acetylcysteine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0